Despite the identification of Epstein-Barr virus (EBV) in tumors of Burkitt's lymphoma (BL) over 40 years ago, the exact contribution of EBV to BL is undefined. EBV encodes for multiple proteins in latent B cells that affect B cell survival and activation. One such protein, latent membrane protein 2A (LMP2A), protects B cells from numerous pro-apoptotic stimuli. Therefore, we tested whether LMP2A protects B cells from apoptosis induced by aberrant c-MYC expression that precedes and dominates BL. We crossed LMP2A-transgenic mice (LMP2A-Tg), in which all B cells express LMP2A, to a transgenic mouse that expresses a BL translocation of myc (k-MYC-Tg mice). LMP2A promotes proliferation and protects B cells from MYC-induced apoptosis in k-MYC-Tg mice. LMP2A also accelerates the development of lymphoma in LMP2A/k-MYC-Tg mice. Finally, LMP2A increases the expression of Bcl-X L in both pretumor B cells and tumor cells, suggesting a mechanism for LMP2A-mediated B cell survival in the presence of MYC. These results support a hypothesis that EBV LMP2A promotes tumor development by protecting pre-tumor B cells that would normally apoptose after the c-myc translocation.
Since the discovery of Epstein-Barr virus (EBV) in a clinical sample of Burkitt's lymphoma (BL) (Epstein et al., 1964) , scientists have proposed a causative role for EBV in BL development. Two forms of BL exist: endemic BL, which is 95% associated with EBV infection, and sporadic BL, which is EBV positive in 15-88% of the cases (Hsu and Glaser, 2000) . Both forms of BL have the canonical c-myc translocation that juxtaposes the myc gene on chromosome 8 with the IgH genes on chromosome 14 or, sometimes, IgL genes on chromosome 2 (Igk) or chromosome 22 (Igl) (DallaFavera et al., 1982; Taub et al., 1982) . Overexpression of c-MYC induces apoptosis and bypassing MYC-induced apoptosis is postulated to be an initiating event that promotes BL (Nilsson and Cleveland, 2003) . Thus, EBV may promote BL development by protecting pre-tumor B cells with a myc translocation from apoptosis.
Transgenic mice constitutively expressing c-MYC in B cells allow for the investigation of factors that promote MYC-dependent tumor development. Many murine MYC-Tg models produce pre-B cell leukemias, B cell lymphomas and/or plasmacytomas (Harris et al., 1988; Park et al., 2005; Kim et al., 2006) . In contrast, Kovalchuk et al. (2000) created l-MYC-Tg mice that re-creates the myc translocation found in BL. These mice develop diffusely infiltrating cervical lymphomas with a 'starry sky' appearance and uniform populations of tumor cells that are similar to the phenotype of cells found in BL (Kovalchuk et al., 2000) . Despite the finding that lymphomas from these mice appear to be derived from more immature B cells (Zhu et al., 2005) , this transgenic system is the closest model of BL available to test the factors that contribute to BL development.
Latent membrane protein 2A (LMP2A) transcripts are consistently detected in all programs of EBV latency, including resting memory B cells, BL, Hodgkin's lymphoma, infectious mononucleosis and post-transplant lymphoproliferative disorder (Tao et al., 1998; Babcock et al., 2000; Thorley-Lawson and Gross, 2004; Bell et al., 2006; Rickinson, 2007) . The presence of LMP2A in all forms of latency suggests the importance of LMP2A for EBV latency and EBV-associated diseases. LMP2A protects human and murine B cells from apoptosis in response to pro-apoptotic stimuli (Fukuda and Longnecker, 2004; Portis and Longnecker, 2004; Mancao et al., 2005; Mancao and Hammerschmidt, 2007) . LMP2A constitutively activates the Ras/ PI3K/AKT pathway, nuclear factor-kB, and increases the levels of Bcl-X L to protect B cells from apoptosis (Portis and Longnecker, 2004; Swanson-Mungerson et al., 2005) . Taken together, these findings indicate that LMP2A could protect B cells in all forms of EBV latency from apoptosis.
LMP2A and EBNA2, an important regulator of LMP2A expression, have been identified in EBV+ germinal center B cells (Babcock et al., 2000; Kurth et al., 2000) . As it is thought that the myc translocation occurs during the germinal center reaction (Zhu et al., 2005) , we hypothesize that LMP2A contributes to BL development by protecting pre-tumor B cells from apoptosis. Due to the inability to test the contribution of LMP2A on the development of BL in humans, we crossed LMP2A-Tg mice to l-MYC-Tg mice (Caldwell et al., 1998; Kovalchuk et al., 2000) . LMP2A and MYC (LMP2A/l-MYC-Tg) mice showed a significant increase in the spleen size (Figures 1a-b) and B cell numbers (Figure 1c ) when compared with the spleens of l-MYC-Tg mice. Flow cytometric analysis indicates that the B cells from the LMP2A/l-MYC-Tg mice show a similar phenotype compared with the l-MYC-Tg mice
) (data not shown). Due to the increase in spleen size in the LMP2A/l-MYC-Tg mice, we carried out hematoxylin and eosin staining to analyse splenic architecture. In contrast to wild-type (WT), LMP2A-Tg and l-MYC-Tg littermates, LMP2A/ l-MYC-Tg mice showed an absence of B cell follicles and an overall loss of normal lymphoid architecture ( Figure 1d ). These results also indicate that the spleens of LMP2A/l-MYC-Tg mice are pre-tumor, as the spleens of these mice do not show a 'starry sky' appearance, which is indicative of lymphoma.
We confirmed the appropriate expression of MYC ( Figure 1e ) and LMP2A ( Figure 1f ) in LMP2A/l-MYCTg and l-MYC-Tg mice. The LMP2A/l-MYC-Tg mice express less LMP2A expression in comparison with the spleens from LMP2A-Tg mice. It seems unlikely that MYC decreases LMP2A expression, as the l-MYC transgene does not affect the immunoglobulin promoter and enhancer (Kovalchuk et al., 2000) that controls LMP2A expression. Alternatively, the LMP2A transgene may be inserted near sequences that are repressed by MYC. As the insertion site of the LMP2A transgene is unknown, it is difficult to determine whether MYC repression is responsible for the observed reduction. Nevertheless, the levels of LMP2A are sufficient to induce dramatic changes in pre-tumor LMP2A/l-MYC-Tg mice.
In addition, the LMP2A/l-MYC-Tg mice show an increased intensity of MYC staining in comparison with the spleens from l-MYC-Tg mice (Figure 1e ), suggesting that LMP2A allows B cells to tolerate higher levels of MYC expression. In the l-MYC-Tg mouse, myc gene expression is controlled by the Igl loci (Gerbitz et al., 1999; Kovalchuk et al., 2000) . It is unlikely that LMP2A activates the endogenous myc promoter to increase MYC levels in the LMP2A/l-MYC-Tg mice, as there is no significant increase in MYC staining in LMP2A-Tg B cells (Figure 1e ). Alternatively, LMP2A may stabilize MYC protein levels in the l-MYC-Tg mouse. Accordingly, LMP2A constitutively activates Ras (Portis and Longnecker, 2004) , which increases and stabilizes MYC protein levels (Vervoorts et al., 2006) . Therefore, LMP2A may promote MYC-induced tumorigenesis by directly affecting MYC levels.
The increase in B cell numbers in LMP2A/l-MYC-Tg mice could be because of an increase in B cell proliferation, a decrease in B cell apoptosis or both. To distinguish among these possibilities, purified B cells from the spleens of LMP2A/l-MYC-Tg and l-MYC-Tg mice were analysed using propidium iodide. As shown in Figure 1g , significantly fewer LMP2A/l-MYC-Tg B cells are apoptotic, as indicated by sub-G o levels of DNA by propidium iodide staining, when compared with B cells from l-MYC-Tg mice. LMP2A/l-MYC-Tg mice also showed an increase in the percentage of cycling B cells. One interpretation of these findings is that LMP2A increases the percentage of B cells proliferating by simply unmasking c-MYC's proliferative potential by protecting these cells from apoptosis. However, as LMP2A augments proliferation in response to mitogenic signals (Ikeda et al., 2004; Swanson-Mungerson et al., 2005 Wang et al., 2006) , and as protecting B cells from MYC-Tg mice from apoptosis is not sufficient for MYC-induced B cell proliferation (Garrison et al., 2008) , it is likely that LMP2A co-ordinates with MYC protein expression to promote cell division.
Since LMP2A promotes MYC-driven cell division while protecting these cells from apoptosis, we analysed tumor onset in these mice. As shown in Figure 2a , LMP2A/l-MYC-Tg mice developed tumors earlier than l-MYC-Tg mice. These data in Table 1 show that LMP2A/l-MYC-Tg mice develop tumors by 85.8 ± 15 days when compared with 136.4 ± 10 days for l-MYC-Tg mice. The l-MYC-Tg and LMP2A/l-MYC-Tg tumors (Swanson-Mungerson et al., 2006) . (e-f) Immunohistochemistry staining of spleen tissues of the transgenic mice using antibodies for (e) MYC (9E10) or (f) LMP2A (14B7) as described earlier (SwansonMungerson et al., 2006) . For panels d-f, the data represent 3-4 mice per genotype. (g) The percentage of cycling and apoptotic B cells was determined when purified B cells were subjected to propidium iodide (PI) staining and analysed by a flow cytometric analysis as described earlier (Fukuda and Longnecker, 2004) . The left-hand side shows representative FACS plots of the PI staining, whereas the bar graph represents a combination of three mice per genotype. *Po0.05 is calculated by Student's t-test. 
) (data not shown). These findings are exciting, as these data indicate that LMP2A, an EBV protein that is not associated with oncogenesis, co-operates with MYC to accelerate tumor development.
Normally, c-MYC decreases the expression of antiapoptotic BCL family members to assure that cells with aberrant MYC expression apoptose. However, this mechanism is bypassed during lymphomagenesis (Eischen et al., 2001) . Additional studies indicate that mice expressing BCL family members and MYC show an accelerated tumor onset (Nilsson and Cleveland, 2003; Linden et al., 2004; Swanson et al., 2004) , splenomegaly and a loss of normal lymphoid architecture in pre-tumor mice (Linden et al., 2004; Swanson et al., 2004) , similar to the LMP2A/l-MYC-Tg mice (Figures 1 and 2) . As LMP2A increases Bcl-X L expression (Portis and Longnecker, 2004) , we analysed Bcl-X L levels in pre-tumor B cells and tumor cells from LMP2A/l-MYC-Tg mice. Spleens from pre-tumor LMP2A/l-MYC-Tg mice showed increased staining for Bcl-X L when compared with that of l-MYC-Tg mice (Figure 3a) . LMP2A-Tg mice also express Bcl-X L (Portis and Longnecker, 2004 ), although at a lower level than LMP2A/l-MYC-Tg mice (Figure 3a) . The mechanism for this increase in Bcl-X L expression in the presence of LMP2A and MYC compared with LMP2A alone is currently unknown. In addition, tumor cells from LMP2A/l-MYC-Tg mice express Bcl-X L (Figure 3b ). To date, no l-MYC-Tg tumor samples are positive for Bcl-X L , which is not surprising because Bcl-X L expression is rare in lymphomas from MYC-Tg mice (Eischen et al., 2001) . All of the Bcl-X L staining is specific, as tissues stained with secondary antibody alone show no positive staining (Figures 3c and d) . On the basis of the literature, c-MYC-induced apoptosis uses either p53 or BIM to block tumorigenesis (Egle et al., 2004; Hemann et al., 2005) . Both BIM and p53-induced PUMA bind to and inactivate members of the BCL-2 family, including Bcl-X L (Youle and Strasser, 2008) . The balance of BCL pro-apoptotic and anti-apoptotic members determines whether cells undergo apoptosis (Youle and Strasser, 2008) . The finding that LMP2A accelerates c-MYC tumorigenesis suggests that LMP2A bypasses one or both of these pathways to promote tumor development. Therefore, if LMP2A increases Bcl-X L to levels that tip the balance to block apoptosis, it will bypass p53-induced PUMA upregulation and/or the presence of BIM in pre-tumorigenic and tumor cells. In addition, LMP2A constitutively phosphorylates and activates the ERK/MAPK pathway (Panousis and Rowe, 1997; Chen et al., 2002; Anderson and Longnecker, 2008; Pan et al., 2008) . As ERK phosphorylation of BIM leads to proteosome-mediated destruction of this protein, LMP2A may utilize this pathway to bypass BIM-mediated apoptosis of B cells with aberrant MYC expression. Taken together, LMP2A-mediated increases in anti-apoptotic Bcl-X L may be sufficient to bypass the MYC-induced p53 and BIM-mediated pro-apoptotic pathways. Further investigations are LMP2A accelerates MYC-induced tumors R Bultema et al warranted to assess these possibilities. Taken together, these findings support a model in which LMP2A-mediated increases in the expression of anti-apoptotic proteins in pre-malignant B cells could protect these cells from apoptosis after a myc-translocation and promote tumor development. We propose that the main role of LMP2A is to function early in disease development before the incurrence of secondary mutations. Once secondary mutations occur, it is possible that high levels of LMP2A are selected against by immune regulation. The need for LMP2A after secondary mutations that protect cells from apoptosis is currently not known and it warrants additional study using both transgenic mouse models and fresh BL biopsies. The data presented herein establish LMP2A as an EBV protein that co-operates with MYC to accelerate tumor development in a mouse model. Additional studies investigating LMP2A and its cooperation with MYC allow for the investigation of EBV in BL and provide basic information on the transformation process of B cell lymphomas. 
